Venture Corporation Limited

Income statement

Sources: FY2022, FY2024, FY2025 Financial Statements; AR2025 Five-Year Financial Highlights. Analyst EBIT = PBT − investment revenue + finance costs − share of associate profit (FX gains retained in operating profit). EBITDA = EBIT + D&A.

Revenue CAGR FY2021–FY2025: −5.0%. Net profit CAGR FY2021–FY2025: −7.7% (analyst calculations).

Commentary.

Revenue cycle: Revenue rose 24.3% in FY2022 on broad-based demand. Healthcare & Wellness, Life Science & Genomics, and Test & Measurement were the significant contributors, despite supply-chain constraints (FY2022 Financial Statements). Three consecutive declines followed: −21.7% in FY2023 on customer destocking and softer demand, −9.6% in FY2024 on "softer customer demand within the Group's portfolio," and −7.4% in FY2025. The FY2025 decline was driven mainly by Lifestyle Consumer and compounded by USD weakness (FY2025 Note A).

Margin resilience is the central financial fact: Revenue fell 34% from peak to FY2025, yet the gross-margin proxy expanded from 24.3% to 27.7%. Management attributes this to a more favourable mix and focus on high value-add solutions (FY2025 Note A). Operating margin compressed by only ~170bp, reflecting the semi-fixed nature of employee costs (flat at ~S$315m despite lower volumes, with Malaysian minimum-wage increases and MYR strength cited in FY2025 Note C) and rising IT spend on an SAP HANA implementation and cloud subscriptions (FY2025 Note F).

Interest income cushioned the profit decline: Investment revenue rose from S$6.8m (FY2021) to S$42.6m (FY2024), equal to ~14% of FY2024 PBT. This kept PBT margin at 11.2% even as operating margin fell below 10%. FY2025 investment revenue eased to S$39.1m as rates declined (FY2025 Note G). This support is rate-sensitive and represents a headwind if rates fall further.

Tax: The effective tax rate rose from 13.1% (FY2021) to ~20% (FY2024–FY2025). The FY2022 Financial Statements cite tax-rate changes at subsidiaries. This structurally lowers net margin relative to the pre-2022 period, and Pillar Two global minimum tax regimes are a further consideration (not quantified by the company in reviewed documents).

Balance sheet

Sources: FY2022, FY2024, FY2025 Financial Statements; AR2025. Working capital = current assets − current liabilities (analyst).

Commentary. Venture carries no bank debt. Its only financial liabilities are leases (S$19.6m at end-FY2025). Cash rose by S$476m between FY2022 and FY2024, primarily because inventory unwound from S$1,065m to S$686m and receivables declined. Goodwill of S$639.7m (~18% of total assets; ~23% of equity) is unchanged across the period. It relates to historic acquisitions, principally GES International (2006). The FY2025 foreign-exchange translation reserve moved from −S$95.8m to −S$178.3m. That move reduced equity and NAV per share (S$10.00 → S$9.71) despite retained earnings, reflecting SGD strength against USD/MYR/RMB. At 30 June 2026, net cash had declined to S$1,108.5m. The decline reflects the S$143.8m FY2025 final dividend, share buybacks, and an inventory build to support growth. Equity attributable was S$2,771.5m and NAV per share S$9.64 (1H2026 Press Release).

Cash flow

Sources: FY2022, FY2024, FY2025 Financial Statements. Working-capital movement = cash generated from operations − operating profit before WC changes (analyst). FCF definition matches the company's FY2023 presentation definition (net cash from operating activities less capital expenditure).

Commentary. Cash generation is countercyclical, as is typical of EMS businesses. Working capital absorbed S$394m during the FY2021–FY2022 upcycle, when inventory was built amid component shortages. It released S$511m in FY2023–FY2024. Capex is light (~0.5–1.6% of revenue), so FCF is largely a function of working-capital swings. Dividends have been held at ~S$218m per year (75 cents) and rose to S$230m in FY2025 (with the special dividend). They exceeded FCF in FY2021, FY2022, and marginally in FY2025, with the shortfall funded from the cash pile. In 1H2026, operating cash flow before working capital was S$154.0m. Net operating cash flow, however, was only S$12.9m because inventories were built ahead of growth (1H2026 Press Release). The year-to-date dividend and buyback outflow therefore drew down cash, consistent with a growth-phase reinvestment of working capital.

Ratios

Methodology: ROE per AR2025 (net profit / average equity). ROIC = NOPAT (analyst EBIT × (1 − effective tax rate)) / (equity attributable + lease liabilities − cash); invested capital includes goodwill. Net debt/EBITDA is negative because net cash exceeds debt (cash / EBITDA shown as negative). DSO uses revenue; DIO and DPO use materials cost; all on year-end balances.

Commentary. ROE has fallen from 13.3% to 8.0%. Part of the decline reflects lower profitability, but part is structural: ~46% of equity was held in cash at end-FY2025, earning roughly 3% pre-tax. ROIC excluding surplus cash remains a healthy 12.9%, still in the mid-teens range of better-run EMS peers (Plexus reported 14.6% ROIC in FY2025). The cash conversion cycle of ~132 days is long relative to large-cap EMS peers (Plexus reported 63 cash-cycle days at fiscal year-end 2025; Celestica 61 days in Q4 2025), though definitions differ. The gap reflects high-mix, long-lead-time component inventory and a deliberate "supply chain assurance" buffer cited in FY2025 and 1H2026. It is the principal lever for further capital efficiency.

Recent quarterly trajectory

Sources: 1Q2025 Business Update; 1H2025 Press Release; The Edge Singapore (3Q2025, 1Q2026); FY2025 press coverage (4Q2025); 1H2026 Press Release. 4Q2025 YoY uses reported 2H figures (2H2025 −5.8%) as the nearest disclosed proxy.

1H2026: revenue S$1,354.7m (+7.4%), net profit S$119.3m (+5.6%), diluted EPS 41.4 cents. On a constant-currency basis, 2Q2026 revenue would have risen 15.4% YoY (1H2026 Presentation). The quarterly inflection — five quarters of flat revenue near S$620–650m, then a 15.6% sequential jump — is the most important data point of the past 18 months.

Management guidance

Management provides qualitative guidance only. As of 6 August 2026 it reported encouraging 1H2026 growth, said the early-year "new shoots" are gaining strength, and expects demand to keep strengthening in Networking & Communications, Test & Measurement Instrumentation, and Semiconductor Related Equipment, per customer feedback. It continues to invest in new opportunities and strategic technology partnerships with customers (1H2026 Press Release).

Consensus expectations

CGSI forecasts average EPS growth of ~8% per year over FY2026–FY2028 (April 2026). PhillipCapital raised its FY2026 PATMI estimate to S$256m (March 2026), implying ~13% growth over FY2025's S$227.0m. One aggregator cites ~4% projected 3-year revenue CAGR (AlphaSpread; date uncertain, likely pre-upgrade). A unified, verified consensus as of October 2026 was not obtained.

Bull case

1. AI-infrastructure growth leg. Portfolio B grew ~S$102m YoY in 2Q2026, and 2Q revenue jumped 15.6% QoQ. If 2H2026 holds the 2Q run-rate (S$726m per quarter), FY2026 revenue would approach S$2.8–2.9bn. That would reverse three years of decline at a ~9% net margin.

2. Mix-driven margin durability. The gross-margin proxy expanded to 27.7% in FY2025 despite falling volume. Operating leverage on a rising top line could lift EBIT margin back toward the 11%+ achieved in FY2021–FY2022.

3. Capital-return optionality. Net cash of S$1.1bn (~21% of market cap at the reference price) supports the higher 30c interim, continued buybacks, and potential accretive acquisitions, while bounding downside.

Bear case

1. Valuation has front-run fundamentals. At ~22.6x trailing P/E (reference price) versus a historic ~14–15x, the stock prices in sustained growth, while FY2025 EPS (78.7c) is still 38% below FY2022 (126.8c).

2. Scale disadvantage in AI hardware. Celestica guides US$17bn of 2026 revenue with ~US$1bn capex. Venture's FY2025 capex of S$25m may be insufficient to win share at scale, and data-centre programmes carry hyperscaler concentration and pricing risk.

3. Cash-flow quality and FX. 1H2026 operating cash flow was only S$12.9m after the inventory build. Reported growth is being eroded by USD weakness (2Q2026: 12.5% reported vs 15.4% constant currency). The Lifestyle Consumer recovery depends on a single customer's next-generation product timing.

Catalysts and monitorables (next 12 months)

Analyst verdict

Venture Corporation enters late 2026 at an inflection point. Its balance sheet is the strongest in its peer group, and its operating model has just proven its resilience. Across FY2023–FY2025, revenue fell by a third from the pandemic-era peak. Yet the company never posted a net margin below 8.9%, expanded its gross-margin proxy to 27.7%, raised its dividend, and ended each year with more than S$1 billion of net cash and no debt. Few contract manufacturers globally have delivered that combination through a downcycle, and it validates the claim that Venture's engineering-intensive, high-mix model earns a structural premium over volume EMS.

The investment question has shifted from resilience to growth. Here the evidence is encouraging but young. The 2Q2026 print (+12.5% YoY, +15.6% QoQ) is the first convincing sign that Portfolio B — data-centre networking, test and measurement, and semiconductor equipment — can replace the faded genomics and lifestyle drivers. However, the recovery rests on two quarters. Venture is a small player in an AI-hardware market dominated by far larger, more capital-intensive rivals. Portfolio A remains in decline pending a single customer's product cycle, and cash conversion weakened sharply in 1H2026 as inventory was rebuilt.

The share price re-rated in anticipation of this growth, from about S$11 in May 2025 to about S$18 in mid-2026. At the reference price, Venture trades near 23x trailing earnings, well above its historical mid-teens multiple. The net-cash cushion and ~4% dividend yield limit downside, but upside now requires sustained double-digit growth and margin expansion in 2H2026–2027.

On balance, Venture is a high-quality franchise with improving momentum and a credible new growth vector. From here, returns depend on execution in AI-related domains rather than on balance-sheet safety alone. Investors should monitor quarterly revenue run-rate, operating cash flow, and the Lifestyle Consumer next-generation ramp as the decisive evidence.

---

Prepared from publicly available information as at 13 October 2026.